Korro Bio Files 8-K for Routine Administrative Update

Ticker: KRRO · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1703647

Korro Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyKorro Bio, Inc. (KRRO)
Form Type8-K
Filed DateJan 9, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: administrative, compliance, corporate-governance

TL;DR

**Korro Bio's 8-K is a standard administrative filing, no big news for traders.**

AI Summary

Korro Bio, Inc. filed an 8-K on January 9, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing primarily serves to update administrative details, such as the company's business address at One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA 02139, and confirm its listing on The Nasdaq Capital Market under the trading symbol KRRO. For investors, this filing indicates routine compliance and no immediate material changes to the company's operations or financial health, suggesting stability rather than significant news.

Why It Matters

This filing is a routine administrative update, confirming basic company information and compliance with SEC regulations. It signals business as usual, without any major operational or financial news that would directly impact stock value.

Risk Assessment

Risk Level: low — The filing contains only administrative information and does not disclose any events that would introduce new risks or uncertainties.

Analyst Insight

A smart investor would note this as a routine compliance filing and not expect any immediate stock price movement based on this information alone. It's a non-event for investment decisions.

Key Numbers

  • $0.001 — par value per share (par value of Korro Bio, Inc.'s common stock)
  • 001-39062 — Commission File Number (SEC file number for Korro Bio, Inc.)
  • 47-2324450 — IRS Employer Identification No. (IRS number for Korro Bio, Inc.)
  • 617-468-1999 — Registrant's telephone number (business phone number for Korro Bio, Inc.)

Key Players & Entities

  • Korro Bio, Inc. (company) — the registrant filing the 8-K
  • January 9, 2024 (date) — date of the earliest event reported and filing date
  • One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA 02139 (address) — principal executive offices of Korro Bio, Inc.
  • KRRO (ticker) — trading symbol for Korro Bio, Inc. common stock
  • The Nasdaq Capital Market (exchange) — exchange where Korro Bio, Inc. common stock is registered
  • $0.001 (dollar_amount) — par value per share of common stock

FAQ

What is the purpose of Korro Bio, Inc.'s 8-K filing dated January 9, 2024?

The 8-K filing by Korro Bio, Inc. on January 9, 2024, is categorized under "Other Events" and "Financial Statements and Exhibits," primarily serving to update administrative information such as the company's business address and confirm its stock listing details.

What is Korro Bio, Inc.'s current business address as stated in the filing?

According to the filing, Korro Bio, Inc.'s principal executive offices are located at One Kendall Square, Building 600-700, Suite 6-401, Cambridge, MA 02139.

On which stock exchange is Korro Bio, Inc.'s common stock traded, and what is its trading symbol?

Korro Bio, Inc.'s common stock is registered on The Nasdaq Capital Market under the trading symbol KRRO.

What is the par value per share of Korro Bio, Inc.'s common stock?

The common stock of Korro Bio, Inc. has a par value of $0.001 per share.

Does this 8-K filing indicate any significant operational or financial changes for Korro Bio, Inc.?

No, this 8-K filing does not indicate any significant operational or financial changes; it primarily provides routine administrative updates and confirms existing company information.

Filing Stats: 426 words · 2 min read · ~1 pages · Grade level 9.9 · Accepted 2024-01-09 09:00:59

Key Financial Figures

  • $0.001 — ich registered Common stock, par value $0.001 per share KRRO The Nasdaq Capital M

Filing Documents

01

Item 8.01. Other Events. On January 9, 2024, Korro Bio, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation of Korro Bio, Inc., dated January 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KORRO BIO, INC. Date: January 9, 2024 By: /s/ Ram Aiyar Name: Ram Aiyar Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.